Pharmacological treatment for sleep apnea
First Claim
1. A method of preventing or ameliorating a sleep-related breathing disorder comprising administering to a patient in need thereof an effective amount of at least one serotonin receptor antagonist, in free base or quaternized form, selected from the group consisting of zatosetron, tropisetron, dolasetron, hydrodolasetron, mescaline, oxetorone, homochlorcyclizine, perlapine, loxapine, olanzapine, chlorpromazine, haloperidol, r (+) ondansetron, cisapride, norcisapride, (+) cisapride, (−
- ) cisapride, (+) norcisapride, (−
) norcisapride, desmethylolanzapine, 2-hydroxymethylolanzapine, and 1-(2-fluorophenyl)-3-(4-hydroxyaminoethyl)-prop-2-en-1-one-O-(2-dimethylaminoethyl)-oxime.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates generally to pharmacological methods for the prevention of amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess serotonin-related pharmacological activity.
-
Citations
16 Claims
-
1. A method of preventing or ameliorating a sleep-related breathing disorder comprising administering to a patient in need thereof an effective amount of at least one serotonin receptor antagonist, in free base or quaternized form, selected from the group consisting of zatosetron, tropisetron, dolasetron, hydrodolasetron, mescaline, oxetorone, homochlorcyclizine, perlapine, loxapine, olanzapine, chlorpromazine, haloperidol, r (+) ondansetron, cisapride, norcisapride, (+) cisapride, (−
- ) cisapride, (+) norcisapride, (−
) norcisapride, desmethylolanzapine, 2-hydroxymethylolanzapine, and 1-(2-fluorophenyl)-3-(4-hydroxyaminoethyl)-prop-2-en-1-one-O-(2-dimethylaminoethyl)-oxime. - View Dependent Claims (2)
- ) cisapride, (+) norcisapride, (−
- 3. A method of preventing or ameliorating a sleep-related breathing disorder comprising administering to a patient in need thereof an effective amount of at least one serotonin receptor antagonist, in quaternized form, selected from the group consisting of ondansetron, ketanserin, risperidone, cyproheptadine, clozapine, methysergide, granisetron, mianserin, ritanserin, cinanserin, LY-53,857, metergoline, LY-278,584, methiothepin, p-NPPL, NAN-190, piperazine, SB-206553, SDZ-205,557, 3-tropanyl-indole-3-carboxylate, and 3-tropanyl-indole-3-carboxylate methiodide.
-
5. A method of preventing or ameliorating a sleep-related breathing disorder comprising administering to a patient in need thereof an effective amount of
(a) at least one of a serotonin receptor antagonist (i) in free base or quaternized form selected from the group consisting of zatosetron, tropisetron, dolasetron, hydrodolasetron, mescaline, oxetorone, homocblorcyclizine, perlapine, loxapine, olanzapine, chlorpromazine, haloperidol, r (+) ondansetron, cisapride, norcisapride, (+) cisapride, (− - ) cisapride, (+) norcisapride, (−
) norcisapride, desmethylolanzapine, 2-hydroxymethylolanzapine, and 1-(2-fluorophenyl)-3-(4-hydroxyaminoethyl)-prop-2-en-1-one-O-(2-dimethylaminoethyl)-oxime,;
(ii) in quaternized form selected from the group consisting of ondansetron, ketanserin, risperidone, cyproheptadine, clozapine, methysergide, granisetron, mianserin, ritanserin, cinanserin, LY-53,857, metergoline, LY-278,584, methiothepin, p-NPPL, NAN-190, piperazine, SB-206553, SDZ-205,557, 3-tropanyl-indole-3-carboxylate, and 3-tropanyl-indole-3-carboxylate methiodide; and
(iii) and mixtures thereof; and
(b) a serotonin receptor agonist. - View Dependent Claims (6, 7, 8, 9, 10, 11, 12)
- ) cisapride, (+) norcisapride, (−
-
13. A method of preventing or ameliorating a sleep-related breathing disorder comprising administering to a patient in need thereof an effective amount of
(a) at least one of a serotonin receptor antagonist (i) in their free base or quaternized form selected from the group consisting of zatosetron, tropisetron, dolasetron, hydrodolasetron, mescaline, oxetorone, homochlorcyclizine, perlapine, loxapine, olanzapine, chlorpromazine, haloperidol, r (+) ondansetron, cisapride, norcisapride, (+) cisapride, (− - ) cisapride, (+) norcisapride, (−
) norcisapride, desmethylolanzapine, 2-hydroxymethylolanzapine, 1-(2-fluorophenyl)-3-(4-hydroxyaminoethyl)-prop-2-en-1-one-O-(2-dimethylaminoethyl)-oxime;
(ii) and in their quaternized form selected from the group consisting of ondansetron, ketanserin, risperidone, cyproheptadine, clozapine, methysergide, granisetron, mianserin, ritanserin, cinanserin, LY-53,857, metergoline, LY-278,584, methiothepin, p-NPPL, NAN-190, piperazine, SB-206553, SDZ-205,557, 3-tropanyl-indole-3-20 carboxylate, and 3-tropanyl-indole-3-carboxylate methiodide; and
(iii) mixtures thereof; and
(b) an effective amount of a selective serotonin reuptake inhibitor. - View Dependent Claims (14, 15)
- ) cisapride, (+) norcisapride, (−
-
16. A method of preventing or ameliorating a sleep-related breathing disorder comprising administering to a patient in need thereof
(a) an effective amount of at least one serotonin receptor antagonist selected from the group consisting of zatosetron, tropisetron, dolasetron, hydrodolasetron, mescaline, oxetorone, homochlorcyclizine, perlapine, ondansetron (GR38032F), ketanserin, loxapine, olanzapine, chlorpromazine, haloperidol, r (+) ondansetron, cisapride, norcisapride, (+) cisapride, (− - ) cisapride, (+) norcisapride, (−
) norcisapride, desmethylolanzapine, 2-hydroxymethylolanzapine, 1-(2-fluorophenyl)-3-(4-hydroxyaminoethyl)-prop-2-en-1-one-O-(2-dimethylaminoethyl)-oxime, risperidone, cyproheptadine, clozapine, methysergide, granisetron, mianserin, ritanserin, cinanserin, LY-53,857, metergoline, LY-278,584, methiothepin, p-NPPL, NAN-190, piperazine, SB-206553, SDZ-205,557, 3-tropanyl-indole-3-carboxylate, and 3-tropanyl-indole-3-carboxylate methiodide; and
(b) at least one selective serotonin reuptake inhibitor selected from the group consisting of fluvoxamine, sertraline, fluoxetine, paroxetine, citalopram, norfluoxetine, r(−
)fluoxetine, s(+)fluoxetine, demethylsertraline, demethylcitalopram, venlafaxine, minacipran, sibutramine, nefazodone, R-hydroxynefazodone, (−
) venlafaxine, and (+)venlafaxine.
- ) cisapride, (+) norcisapride, (−
Specification